Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company....

menu
menu